



**Universiteit
Leiden**
The Netherlands

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models

Tsonaka, R.; Signorelli, M.; Sabir, E.; Seyer, A.; Hettne, K.; Aartsma-Rus, A.; Spitali, P.

Citation

Tsonaka, R., Signorelli, M., Sabir, E., Seyer, A., Hettne, K., Aartsma-Rus, A., & Spitali, P. (2020). Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models. *Human Molecular Genetics*, 29(5), 745-755. doi:10.1093/hmg/ddz309

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](https://creativecommons.org/licenses/by-nc/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3184634>

Note: To cite this publication please use the final published version (if applicable).

GENERAL ARTICLE TWO

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models

Roula Tsonaka¹, Mirko Signorelli^{1,2}, Ekrem Sabir², Alexandre Seyer³, Kristina Hettne², Annemieke Aartsma-Rus² and Pietro Spitali^{2,*}

¹Biomedical Data Sciences, Leiden University Medical Center, Leiden 2333 ZC, The Netherlands, ²Department of Human Genetics, Leiden University Medical Center, Leiden 2333 ZC, The Netherlands and ³Profilomic SA, Boulogne-Billancourt 92100, France

*To whom correspondence should be addressed. Tel: +31 715269437; Fax +31 715268285; Email: p.spitali@lumc.nl

Abstract

Duchenne muscular dystrophy is a severe pediatric neuromuscular disorder caused by the lack of dystrophin. Identification of biomarkers is needed to support and accelerate drug development. Alterations of metabolites levels in muscle and plasma have been reported in pre-clinical and clinical cross-sectional comparisons. We present here a 7-month longitudinal study comparing plasma metabolomic data in wild-type and *mdx* mice. A mass spectrometry approach was used to study metabolites in up to five time points per mouse at 6, 12, 18, 24 and 30 weeks of age, providing an unprecedented in depth view of disease trajectories. A total of 106 metabolites were studied. We report a signature of 31 metabolites able to discriminate between healthy and disease at various stages of the disease, covering the acute phase of muscle degeneration and regeneration up to the deteriorating phase. We show how metabolites related to energy production and cachexia (e.g. glutamine) are affected in *mdx* mice plasma over time. We further show how the signature is connected to molecular targets of nutraceuticals and pharmaceutical compounds currently in development as well as to the nitric oxide synthase pathway (e.g. arginine and citrulline). Finally, we evaluate the signature in a second longitudinal study in three independent mouse models carrying 0, 1 or 2 functional copies of the dystrophin paralog utrophin. In conclusion, we report an in-depth metabolomic signature covering previously identified associations and new associations, which enables drug developers to peripherally assess the effect of drugs on the metabolic status of dystrophic mice.

Introduction

Duchenne muscular dystrophy (DMD) is a rare neuromuscular disorder affecting 1 in 5000 male births (1). Patients with DMD become wheelchair dependent by the age of 10–12 years of age and die prematurely due to cardio-pulmonary complications in

the 2nd–4th decade. The disease is caused by mutations in the dystrophin encoding DMD gene (2). There is currently no cure for the disease; however, the implementation of standards of care and chronic use of corticosteroids has significantly improved patients' quality of life. In recent years, a number of therapeutic compounds have been tested in clinical trials in DMD (3), and

Received: October 18, 2019. Revised: November 26, 2019. Accepted: December 16, 2019

© The Author(s) 2020. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

For commercial re-use, please contact journals.permissions@oup.com

two compounds received conditional and accelerated approval by the EU (4) and USA (5) regulatory authorities, respectively.

Therapies currently in development for DMD aim to slow down disease progression, which poses challenges on evaluating drug efficacy in clinical trials. While DMD is a progressive disease leading to the irreversible loss of function in patients, the functional decline during the duration of a clinical trial (6–24 months) as picked up with functional outcome measures is generally limited and can vary greatly between patients. In fact, many clinical trials failed to pick up a therapeutic effect (i.e. slower disease progression). This could be due to poor drug potency, but also to non-optimal trial design, insensitive and/or non-optimal outcome measures and to inter-individual variability in patients' performance. Retrospective analysis showed that the power of clinical trials has been overestimated, due to assumptions that later turned out to be incorrect. For example, a recent phase 3 trial failed with an observed power of 0.53 in contrast to a pre-specified power of 0.9 (6).

These failures led to a number of research initiatives aimed at identifying biomarkers in blood and urine to be used as surrogate or secondary endpoints in clinical trials. Recent research has enabled the identification of multiple proteins (7–14) and miRNAs (15–19) able to separate healthy and DMD cases in cross-sectional studies. These studies have shown the diagnostic potential of these biomarkers without assessing their value in monitoring disease progression. So far, only a few studies have explored whether metabolites in the blood stream could serve as biomarkers in DMD patients (20–22) and DMD animal models (23,24). The focus of those studies has mainly been on the identification of a metabolic signature between healthy and disease in a cross-sectional manner. However, it is also important to know the long-term trajectories of these biomarkers, and how they correlate to or are predictive of pathology and function. Therefore, we here focus on the identification of longitudinal changes representative of disease progression in mice derived plasma samples. We present a prospective 7-months longitudinal study in which we obtained plasma samples from wild-type (WT) and *mdx* mice (the most used murine model of DMD carrying a nonsense mutation in the *Dmd* gene) at five different time points. We identified a signature of 31 metabolites in plasma able to discriminate between *mdx* and WT at different stages of the disease. We further compared the identified 31 metabolites in dystrophin negative mice carrying 2, 1 or no functional copies of the *Utrn* gene, encoding utrophin, which is a dystrophin paralog able to compensate to some extent for lack of dystrophin in mice. In fact, utrophin upregulation is one of the therapeutic approaches in development for DMD (25).

The presented study is the first of its kind with multiple phased longitudinal samples spanning a period of 7 months. The collected data show that metabolomic signatures are able to detect a disease progression signature beyond the known degeneration/regeneration phase known to occur in the first 10–12 weeks of the disease. The identified signature further shows how pathways targeted by drugs in development such as metformin could be monitored by studying the metabolomic signature in peripheral blood.

Results

WT and *mdx* mice were included in the experiment starting from 4 weeks of age. Plasma samples were obtained at five time points at 6, 12, 18, 24 and 30 weeks of age as indicated in Figure 1A. Skeletal muscles were isolated after sacrifice at 30 weeks of age. Mouse weight was recorded before and after fasting. *Mdx*

mice were on average heavier compared with WT mice (Fig. 1B). H&E staining on tibialis anterior muscles obtained at 30 weeks of age showed an increase percentage of fibrotic/inflammatory/necrotic tissue compared with healthy mice, confirming the expected alterations due to the lack of dystrophin (Fig. 1C). A metabolomic approach was taken to identify non-invasive biomarkers during *mdx* mice disease progression. This analysis provided a list of 106 metabolites, most of which were amino acids, peptides and analogs (Fig. 1D). We performed unsupervised clustering on all samples as initial data exploration to assess whether clustering of WT and *mdx* mice could indicate the presence of a signature able to separate the two strains. Indeed, a reasonable clustering was observed between the two genotypes with a good but not complete separation of WT and *mdx* mice (Fig. 1E). This initial exploration showed that a potential signature is present in the data. To visualize the strength of correlations in the data set, we clustered the correlation matrix across metabolites showing that some correlation exist in the data set (Fig. 1F).

Given the availability of up to five repeated measurements per mouse, we analyzed all metabolites with linear mixed models that account for the longitudinal nature of the data. We tested for differences in mean profiles at any time point between *mdx* and WT mice by testing whether both the main effect of group and its interaction terms with time are null. A comparison between the obtained and expected *P*-values (in case of no difference between groups) highlighted the presence of many metabolites differentially represented in *mdx* mice (Fig. 2A). A total of 31 metabolites showed significant differences between *mdx* and WT mice (FDR <5%). The majority of differences between *mdx* and WT mice were observed between weeks 12 and 24, with only minor differences observed at 6 weeks of age. Seven metabolites showed overall reduced relative levels in *mdx* compared with WT, while the remaining 24 were increased in *mdx*. Dipeptides normally highly represented in muscle tissue such as carnosine and anserine (Fig. 2B and C) showed a persistent increase in *mdx* compared with WT, while amino acids such as ornithine and glutamine (Fig. 2D and E) were reduced in *mdx* mice in accordance with previous reports in patients (20,21). A list of the significant differences between *mdx* and WT for each time point is presented in Supplementary Material, Table S1, while trajectory plots for metabolites are presented in Figure 2 and Supplementary Material, Figure S1. Only citrulline and tryptophan showed significant differences at all time points, with an inversion in directional changes at 6 weeks of age compared with the later sampling times (Supplementary Material, Figure S1). Metabolites in the guanidinoacetic acid, creatine and creatinine axis were elevated in *mdx* mice (Fig. 2F–H). While the elevation of creatine in *mdx* mice is in line with the previously reported elevation in patients (21,22), guanidinoacetic acid was previously reported to be reduced in patients (21). Creatinine showed a non-significant trend towards an increase in *mdx* mice, again showing a difference compared to patients (21). Supplementary Material, Figure S2 shows the individual mice trajectories for the significant associations presented in Figure 2. A number of nucleosides derivatives (methyladenosine, methylguanine and cytidine) were elevated in *mdx* mice as well multiple metabolites involved in amino acid conversions were significantly affected (Supplementary Material, Figure S1).

Pathway analysis of the data was performed with the global test. A total of 25 pathways were found to be significant (Supplementary Material, Table S2). Pathways affected showed that some of the metabolites belonging to the same pathways provided a significant and opposite contribution to the pathway




Figure 1. Overview of the study and obtained data. (A) Scheme showing the study design. Vertical arrows indicate at what age blood samples were obtained. (B) Line graph showing the weight progression in *mdx* and WT mice during the study. Weight before fasting is plotted on the y-axis, while age in weeks is plotted on the x-axis. (C) The percentage of unhealthy tissue composed of fibrotic tissue inflammatory infiltrate, and necrotic fibers was quantified after H&E staining of sections obtained from the tibialis anterior muscle of 30-weeks-old *mdx* ($n=4$) and WT ($n=5$) mice. (D) Table showing the counts of metabolites for each class identified by the analytical platform. (E) Heat map with all samples showing hierarchical clustering on both columns and rows based on Euclidean mean distance. Genotype and sampling time (in weeks) is presented for each column. (F) Heatmap of the Pearson correlation across metabolites in all samples shows moderate correlation across the identified metabolites.




Figure 2. (A) Q-Q plot showing the enrichment in high $-\log_{10}$ observed P -global (black dots) for each metabolite compared with the expected distribution. (B–E) Line plots of scaled data showing examples for elevated levels of carnosine and anserine in *mdx* mice compared with WT mice, and decreased levels of ornithine and citrulline in *mdx* plasma. (F–H). Line plots of scaled data showing the plasma levels of guanidinoacetic acid, creatine and creatinine in *mdx* mice compared with WT mice.

significance (Fig. 3A–D). Interestingly, network analysis showed how several metabolites with reduced plasma levels in *mdx* mice were amino acids downstream the NO precursor arginine, which was found to be elevated in *mdx* mice (Fig. 3E).

The data obtained in *mdx* mice revealed the presence of a metabolic endo-phenotype in these mice. The observed changes were consistent for the whole study duration supporting a role of these metabolites in disease progression. To further test whether the 31 metabolites identified in the comparison between *mdx* and WT mice were associated with disease trajectories and disease severity, we studied *mdx* mice carrying 0, 1 or 2 functional copies of the dystrophin paralog utrophin, as utrophin gene dosage has been linked to disease progression in *mdx* mice (26). Plasma samples were obtained at 6, 12, 18, 24 and 30 weeks of age for mice carrying either 1 or 2 functional *Utrn* alleles, while for double knock-out mice samples were only obtained at 6 weeks of age given the severe phenotype of these mice. The levels of propionylcarnitine and methylimidazoleacetic acid appear to relate to the number of functional *Utrn* copies ($P < 0.05$); however, the association was not significant after multiple testing correction ($FDR > 5\%$). Line plots for propionylcarnitine and methylimidazoleacetic acid are presented in Figure 4, while line plots for the

other 29 metabolites are presented in Supplementary Material, Figure S3. Double knock-out mice showed elevated levels of both metabolites at baseline compared with mice carrying at least one *Utrn* functional allele. Furthermore, mice carrying one functional *Utrn* gene showed higher levels of propionylcarnitine and methylimidazoleacetic acid compared with the mice with two functional alleles. Specifically, propionylcarnitine showed elevation at 12 ($P = 0.02$) and 24 weeks ($P = 0.07$) of age, while methylimidazoleacetic acid showed a significant increase at 24 weeks ($P = 0.007$). Interestingly, changes between *mdx* and WT mice were also identified for the same time points with propionylcarnitine being elevated at 12 weeks of age in *mdx* mice and methylimidazoleacetic acid being elevated at 18, 24 and 30 (Fig. 4C and D).

Discussion

DMD is rare genetic condition caused by mutations in the DMD locus resulting in the lack of dystrophin protein. A number of omics studies have been performed especially in skeletal muscle tissue obtained from patients and animal models to understand the biology of the disease, to identify drug




Figure 3. (A–D) Examples of pathways affected. Each panel shows a different pathway. Metabolites contributing to the pathway are graphed as bars at the bottom of each panel. The P-values displayed on the y-axis show how significant is the contribution of each metabolite to the pathway score. Bars in green are associated with the WT group (higher in WT mice), while bars in red are associated with the *mdx* group (higher in *mdx* mice). Hierarchical clustering is based on the absolute correlation distance between metabolites. Thick lines indicate a metabolite of a cluster of metabolites significantly contributing to the overall global test score. (E) Example of network involving significant amino acids identified in this study. Metabolites significantly affected are represented in yellow. The network was built using the Metscape app in Cytoscape.

targets and more recently to understand what molecules could be used as biomarkers. While the analysis of muscle biopsies provides direct information about the muscle, less invasive readouts are needed in order to provide objective

biological information during disease progression and drug testing. The focus of biomarker research is the identification of pharmacodynamic biomarkers able to show dose-response to medicinal drugs, as well as biomarkers associated with




Figure 4. (A and B). Line graphs of normalized data showing the effect of utrophin dosage on the plasma levels of propionylcarnitine and methylimidazoleacetic acid. (C and D). Corresponding bar graphs showing the change in propionylcarnitine and methylimidazoleacetic acid in *mdx* mice compared with WT mice.

disease progression in order to anticipate disease milestones and eventually substitute clinical endpoints in clinical trials. Most of the omics research focused on the identification of genetic modifiers (27), gene expression by microarray (28–32) and RNAseq (19), protein abundance by mass spectrometry (8,33–35) and affinity assays (7,9–11,36,37). Studies of metabolites involving muscle tissues have been somewhat less covered with one study showing analysis of muscle biopsies obtained from multiple forms of muscular dystrophy (38) and a few studies reporting changes in dystrophic mice (24) and golden retriever muscular dystrophy (GRMD) dogs (39). These studies clarified the pathophysiology of the disease including the energy deficit in DMD.

Clear associations included the impaired energy production in DMD muscle such as the reduction in glutamine levels in muscle tissue (38). Glutamine is mostly produced by muscle mass in the body (40), and it is one of the major energy sources for muscle cells (41). Glutamate/glutamine levels have been found to be increased in *mdx* muscle consistently at 3, 6 and 12 months of age (42,43) but reduced in DMD patients muscle (38). The described increase of glutamine levels in *mdx* muscle is opposed to our observation in plasma, where a persistent reduction is present starting from week 12 up to 30 weeks of age. It is possible that mice may compensate for the lack of energy in

muscle fibers, caused by the known reduction in creatine concentration (43), with increased glutamine consumption; the augmented glutamine use by muscle would then be mirrored by reduced glutamine levels in circulation, such as in cachectic conditions (44,45). In DMD patients, glutamine levels are reduced in muscle (38) but unaffected in plasma (21), consistent with the inability of patients' muscle to increase glutamine metabolism and compensate for the known reduction of creatine (46–48) and its energy buffering capacity. Glutamine synthesis depends on intermediates of the tricarboxylic acid (TCA) cycle such as fumarate, which has been shown to be reduced in DMD muscle biopsies (38), and alpha-keto glutarate. Metabolites of the TCA cycle have been shown to be affected in dystrophic mice (49) and dystrophic dogs (39). Further evidence from gene expression studies in GRMD dogs (50) but also from proteomic profiling in patients' blood (10) show that enzymes of the TCA cycle are affected in DMD. Glutamine reduction can also be linked to the pathway leading to the synthesis of nitric oxide synthase (nNOS), a key player in DMD pathophysiology (51). Indeed, glutamine can be converted into citrulline, which is the only precursor for arginine synthesis (52). Our data show that both glutamine and citrulline are reduced in *mdx* mice, while arginine levels are elevated. Arginine is then converted in nitric oxide by nNOS, a direct dystrophin binder, which is typically displaced by the lack of

dystrophin (53). Interestingly, supplementation of arginine and metformin showed improved muscle function in an open-label proof of concepts study (54). A follow-up double blind placebo controlled study was then planned substituting arginine with citrulline with the same intent (55). These metabolites could therefore be explored as pharmacodynamic readouts in such trials. Reduced glutamine levels could also be due to the reduced glutamine synthetase activity, which has been connected to the extrahepatic (and in particular muscular) ammonia detoxification (56), a pathway particularly significant in our data set.

Reduced energy capacity is also evident by the previously published evidence that the guanidinoacetic acid—creatine—creatinine axis is affected in DMD (22,57) and that the ratio between creatine and creatinine is associated with patients performance (21). Interestingly, *mdx* mice show increased plasma levels of all three metabolites, while patients show increased creatine and reduced guanidinoacetic acid and creatinine, underlining again the differences in metabolic capacity of *mdx* muscles compared with DMD muscles.

We further show that histidine, one of the glucogenic amino acids, is reduced in *mdx* mice plasma. Reduction of histidine levels could be related to the synthesis of carnosine, which is synthesized by carnosine synthase starting from histidine and beta-alanine. Carnosine levels were shown to be reduced in *mdx* muscles (43) and we report here an increase of carnosine levels in blood leading to postulate a release/leakage of carnosine to the blood stream in *mdx* mice. Carnosine is a dipeptide highly present in muscle, which is linked to muscle buffering capacity in muscle fibers. Elevated synthesis of carnosine via carnosine synthase could deplete histidine levels in an attempt to improve muscle buffering. This theory could be supported by the increased anserine levels in the plasma of *mdx* mice, which could also be produced by carnosine synthase starting from 3-methylhistidine.

By comparing mice carrying different functional utrophin copies, we did not identify metabolites able to separate mice with different functional *Utrn* copy number. However, propionylcarnitine and methylimidazoleacetic acid showed elevated profiles in more severely affected mice. The elevation of propionylcarnitine could be linked to the mitochondrial dysfunction. In type 2 diabetes, propionylcarnitine has been shown to be the predictive of mitochondrial dysfunction in muscle (58); DMD patients show some molecular characteristics of metabolic syndrome such as elevated serum leptin levels (7,59), and propionylcarnitine could indicate the known mitochondrial dysfunction associated with the lack of dystrophin. On the other hand, increased levels of methylimidazoleacetic acid could be related to performance via the histamine metabolism. Indeed, methylimidazoleacetic is the end product of the histamine catabolism, which is related to blood vessel dilation and permeability. Treatment with histamine and serotonin showed a beneficial effect on dystrophic mice (60). The net effect of histamine is however unclear as the improvement could also be due to the serotonin, which is in fact synthesized starting from tryptophan, which we describe here to be reduced in *mdx* compared with WT mice.

Our data partly overlap with recently published data (23,24,57) in dystrophic mice, such as alterations in metabolites mapping to the TCA cycle and glutamine identified in 4 to 6 months old *Dmd*^{mdx-4Cv} mice (23) or the creatine increase identified in *mdx* BL10 mice (24). However, the differences across analytical platforms (such as in the study by Lee-McMullen *et al.* where NMR is used), study design (our study is longitudinal while previous studies are cross-sectional), genetic background (we

use BL10 *mdx*, while Joseph *et al.* report on *Dmd*^{mdx-4Cv}) and sample numbers are likely responsible for the different observations.

A strong point in our study is the availability of repeated measurements; published studies so far showed only single measurements per individual mouse, therefore limiting the possibility to model disease progression at the individual level. A weak point is the number of animals involved, which is limited to five per group but in line with previous publications; however, the availability of repeated measurement allowed us to increase the power to reliably identify the metabolic signature (61).

In this study, we have provided an in depth characterization of the circulating metabolites in four mouse models of DMD. The longitudinal follow-up of mice over a period of 30 weeks allowed us to model individual trajectories over the different phases of the disease, encompassing the highly regenerative phase up to the deteriorating phase. This enabled us to show that peripheral metabolic changes are less evident in young mice where performance is less affected but histological findings are more pronounced; in contrast, metabolites show a stronger signature at later stages when histology is improved but performance is worsening. We have shown how different metabolites are connected to the pathophysiology and to the mechanism of action of nutraceuticals and pharmaceuticals in development in the DMD space. The collected data will be helpful to evaluate the effects of drugs targeting dysregulated metabolic pathways such as the application of citrulline and metformin or serotonin and histamine. Furthermore, detailed reconstruction of metabolic flux over time could enable to propose therapeutic agents with potential beneficial effect in dystrophinopathies.

Materials and Methods

Mice

WT and *mdx* mice (five per group) were included in the experiment starting from 4 weeks of age. Only male mice were included in the experiment. Mice were kept in individually ventilated cages and were fed *ad libitum* with chow and had free access to water. Blood samples were obtained via the tail vein when mice were 6, 12, 18 and 24 weeks of age and from the eye at week 30. Mice were fasted for 4–6 h before sampling; during this time, they had free access to water. Mice were anaesthetised with isoflurane before sampling, and a solution of lidocaine and adrenaline was applied on the tail cut before they were allowed to wake up from anaesthesia. Blood samples were obtained in heparin lithium tubes. Mice were sacrificed by cervical dislocation after the last sample was collected at 30 weeks of age. Muscles were then collected as well, and H&E staining was performed to quantify the proportion of unhealthy tissue (fibrosis, necrosis and inflammation) over the total as previously described (62). To test whether differences in disease severity existed, we included mice with different copy number of functional utrophin alleles. Five mice per group were included. Plasma samples were obtained at 6, 12, 18, 24 and 30 weeks of age for mice carrying 1 or 2 functional copies of utrophin, while for double knock-out mice, only samples at 6 weeks of age were collected. Double knock-out mice were sacrificed at 6 weeks of age as they were too severely affected to be kept. The experiment was evaluated and approved by the local animal welfare committee under DEC number 13154.

Sample preparation and data acquisition

Plasma samples were kept on ice and centrifuged at 18 000*g* for 5 min at 5°C. After centrifugation, the supernatant was aliquoted

and frozen at -80°C pending use. The sample order of the sample preparation and the analytical batch was randomized to avoid bias. The procedure for data acquisition has been previously described for the analysis of human plasma (21). Briefly, plasma samples were introduced into a Transcend 1250 LC (Thermo Fisher Scientific) fitted with a Sequant ZICpHILIC 5 μm , 2.1×150 mm column (Merck). This was then coupled to a Q-Exactive mass spectrometer (Thermo Scientific) in both positive and negative ionization modes, alternatively.

Data analysis (peak picking and features annotation) was performed using TraceFinder 3.1 (Thermo Fisher Scientific). Annotation was based on the exact m/z ratio of the pseudo-molecular $[\text{M} + \text{H}]^+$ or $[\text{M} - \text{H}]^-$ ions in positive and negative mode, respectively (± 5 ppm mass tolerance); retention time and isotopic pattern were also used to align to an in-house database of authentic standard compounds. The obtained data set was cleaned based on several parameters as described by Dunn *et al.* (63). The coefficients of variation of the areas of chromatographic peaks of features in QC samples (pool of each sample analyzed every five samples) should be below 30%, the coefficient of correlation between QC dilution factors (series of dilution of the QC sample) and areas of chromatographic peaks should be above 0.7 and the ratio of chromatographic peak areas of biological to blank samples above a value of 3.

After LC-MS analysis of samples and annotation of features, QC samples were re-injected for higher energy collisional dissociation MS/MS experiments in positive and negative ion modes on the same instrument set in targeted mode using inclusion lists. Only features that match with the MS/MS spectrum of the corresponding chemical standard were kept. These annotations correspond to the level 1 according to the Metabolomics Standards Initiative (64). Relative quantification was finally performed by comparing raw areas of identified compounds. For metabolites detected and identified in both negative and positive modes, only the data obtained in negative mode were included in the data analysis given that most metabolites were detected in that mode. Data are available as Supplementary Material with Supplementary Material, Table S3 providing the data used to compare WT and *mdx* mice and Supplementary Material, Table S4 reporting the data used to compare *mdx* mice with different functional copies of utrophin.

Statistics

A preliminary analysis of the raw metabolomics data highlighted considerable differences in the order of magnitude of metabolite concentrations; to correct for this, auto-scaling was employed to normalize the raw data, dividing the concentration levels of each metabolite at each time point by its standard deviation (65).

Visual exploration of the normalized data was performed by generating a heatmap where both samples and metabolites were clustered using the average linkage method in combination with the Euclidean distance. We employed linear mixed models (66) to study the dynamic evolution of each metabolite over time and to identify differences between WT and *mdx* mice at different time points. We considered a linear mixed model where the concentration of a metabolite in sample j from individual i , y_{ij} , depends on time (categorical), strain (WT and *mdx*) and their interactions as fixed effects, as well as on mice-specific random intercepts u_{i0} and slopes u_{i1} :

$$y_{ij} = \beta_0 + \beta_1 w_{12ij} + \beta_2 w_{18ij} + \beta_3 w_{24ij} + \beta_4 w_{30ij} + \text{mdx} (\beta_5 + \beta_6 w_{12ij} + \beta_7 w_{18ij} + \beta_8 w_{24ij} + \beta_9 w_{30ij}) + u_{i0} + u_{i1} t_{ij} + \varepsilon_{ij},$$

where w_{12ij} , w_{18ij} , w_{24ij} , and w_{30ij} are dummy variables indicating whether sample j was obtained at week 12, 18, 24 or 30, mdx_i is a dummy whether mouse i is *mdx* (1) or WT (0), t_{ij} denotes time (in weeks), $u_{i0} \sim N(0, \sigma_0^2)$ and $u_{i1} \sim N(0, \sigma_1^2)$ are Gaussian random effects and $\varepsilon_{ij} \sim N(0, \sigma_\varepsilon^2)$ is a Gaussian error term. The statistical significance of differences between WT and *mdx* mice at any time point was assessed by testing the null hypothesis $H_0: \beta_5 = \beta_6 = \beta_7 = \beta_8 = \beta_9 = 0$ with the likelihood ratio test statistic; the P-values obtained from such test ('p-global') were then adjusted with the Benjamini-Hochberg method (FDR) (67) to account for multiple testing. Metabolites with statistically significant profiles between the two groups (FDR < 5%) were further investigated testing differences between the two groups at each time point using the Wald test.

For the 31 metabolites that displayed significant differences between WT and *mdx* comparison, we further checked whether differences existed between *mdx* mice with different utrophin copy numbers, focusing our attention on mice with 1 and 2 copy numbers (due to the fact that all mice with 0 copy numbers were sacrificed after week 6 and no samples were thus available for the subsequent time points). We considered a linear mixed model where the concentration of each metabolite depends on time (categorical), strain (*mdx* mice with 1 or 2 copy numbers) and their interactions as fixed effects, as well as on mice-specific random intercepts and slopes. The statistical significance of differences between the two mice groups at any time point was tested with the likelihood ratio test, and P-values were adjusted with the Benjamini-Hochberg method (FDR) (67).

Pathway analysis was performed with the global test (68). As pathway analyses pipeline are developed for cross-sectional but not for longitudinal data, for each mouse, we derived a summary of the trajectories described by the metabolites computing the area under the profile of each metabolite. WikiPathways were used as source for the metabolic pathways (69). Pathway information from WikiPathways was mined using an internal workflow that interacts with the application programming interface services of WikiPathways (70). Workflows created with the open source software Taverna Workbench (71) can be found at <http://www.myexperiment.org/packs/689>. All pathways and corresponding metabolites were downloaded. P-values from the global test were adjusted using the max T test correction (72).

Cluster analysis of the metabolites was performed using Morpheus (73). The statistical analyses described in this paper were performed using R. We used the R package *nlme* (74) to estimate the linear mixed models and the R package *globaltest* (68) to compute the global test. Network visualization was performed using the MetScape App (75) in Cytoscape (76).

Supplementary Material

Supplementary material is available at HMG online.

Acknowledgements

The authors would like to acknowledge Laura van Vliet for performing the H&E staining of muscle sections.

Conflict of Interest statement. The authors declare no competing interests.

Funding

European Commission through the projects Neuromics (No. 305121); RD-Connect (No. 305444); Duchenne Parent Project NL.

References

- Mercuri, E. and Muntoni, F. (2013) Muscular dystrophies. *Lancet (London, England)*, **381**, 845–860.
- Tuffery-Giraud, S., Saquet, C., Thorel, D., Disset, A., Rivier, F., Malcolm, S. and Claustres, M. (2005) Mutation spectrum leading to an attenuated phenotype in dystrophinopathies. *Eur. J. Hum. Genet.*, **13**, 1254–1260.
- Mercuri, E. and Muntoni, F. (2013) Muscular dystrophy: new challenges and review of the current clinical trials. *Curr. Opin. Pediatr.*, **25**, 701–707.
- Haas, M., Vlcek, V., Balabanov, P., Salmonson, T., Bakchine, S., Markey, G., Weise, M., Schlosser-Weber, G., Brohmann, H., Yerro, C.P. et al. (2015) European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. *Neuromuscul. Disord.*, **25**, 5–13.
- Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., Alfano, L., Gomez, A.M., Lewis, S., Kota, J. et al. (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. *Ann. Neurol.*, **74**, 637–647.
- Goemans, N., Mercuri, E., Belousova, E., Komaki, H., Dubrovsky, A., McDonald, C.M., Kraus, J.E., Loubakos, A., Lin, Z., Campion, G. et al. (2018) A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. *Neuromuscul. Disord.*, **28**, 4–15.
- Spitali, P., Hettne, K., Tsonaka, R., Charroux, M., van den Bergen, J., Koeks, Z., Kan, H.E., Hooijmans, M.T., Roos, A., Straub, V. et al. (2018) Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. *J. Cachexia. Sarcopenia Muscle*, **9**, 715–726.
- Oonk, S., Spitali, P., Hiller, M., Switzar, L., Dalebout, H., Calissano, M., Lochmüller, H., Aartsma-Rus, A.A., 't Hoen P.E., van der B.Y. et al. (2015) Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients. *Proteomics. Clin. Appl.*, **10**.
- Hathout, Y., Brody, E., Clemens, P.R., Cripe, L., DeLisle, R.K., Furlong, P., Gordish-Dressman, H., Hache, L., Henricson, E., Hoffman, E.P. et al. (2015) Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. *Proc. Natl. Acad. Sci.*, **112**, 7153–7158.
- Ayoglu, B., Chaouch, A., Lochmüller, H., Politano, L., Bertini, E., Spitali, P., Hiller, M., Niks, E., Gualandi, F., Pontén, F. et al. (2014) Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. *EMBO Mol. Med.*, **6**, 1–19.
- Burch, P.M., Pogoryelova, O., Palandra, J., Goldstein, R., Bennett, D., Fitz, L., Guglieri, M., Bettolo, C.M., Straub, V., Evangelista, T. et al. (2017) Reduced serum myostatin concentrations associated with genetic muscle disease progression. *J. Neurol.*, **264**, 541–553.
- Burch, P.M., Pogoryelova, O., Goldstein, R., Bennett, D., Guglieri, M., Straub, V., Bushby, K., Lochmüller, H. and Morris, C. et al. (2015) Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. *J. Neuromuscul. Dis.*, **2**, 241–255.
- Coenen-Stass, A.M.L., McClorey, G., Manzano, R., Betts, C.A., Blain, A., Saleh, A.F., Gait, M.J., Lochmüller, H., Wood, M.J.A. and Roberts, T.C. et al. (2015) Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. *Sci. Rep.*, **5**, 17014.
- Guiraud, S., Edwards, B., Squire, S.E., Babbs, A., Shah, N., Berg, A., Chen, H. and Davies, K.E. (2017) Identification of serum protein biomarkers for utrophin based DMD therapy. *Sci. Rep.*, **7**, 43697.
- Zaharieva, I.T., Calissano, M., Scoto, M., Preston, M., Cirak, S., Feng, L., Collins, J., Kole, R., Guglieri, M., Straub, V. et al. (2013) Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy. *PLoS One*, **8**, e80263.
- Cacchiarelli, D., Legnini, I., Martone, J., Cazzella, V., D'Amico, A., Bertini, E. and Bozzoni, I. (2011) miRNAs as serum biomarkers for Duchenne muscular dystrophy. *EMBO Mol. Med.*, **3**, 258–265.
- Jeanson-Leh, L., Lameth, J., Krime, S., Buisset, J., Amor, F., Le Guiner, C., Barthélémy, I., Servais, L., Blot, S., Voit, T. and Israeli, D. (2014) Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in golden retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients. *Am. J. Pathol.*, **184**, 2885–98.
- Coenen-Stass, A.M.L., Betts, C.A., Lee, Y.F., Mäger, I., Turunen, M.P., El Andaloussi, S., Morgan, J.E., Wood, M.J.A. and Roberts, T.C. (2016) Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation. *Hum. Mol. Genet.*, **25**, 3960–3974.
- Coenen-Stass, A.M.L., Sork, H., Gatto, S., Godfrey, C., Bhomra, A., Krjutškov, K., Hart, J.R., Westholm, J.O., O'Donovan, L., Roos, A. et al. (2018) Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMD. *Mol. Ther. – Nucleic Acids*, **13**, 1–15.
- Srivastava, N.K., Annarao, S. and Sinha, N. (2016) Metabolic status of patients with muscular dystrophy in early phase of the disease: in vitro, high resolution NMR spectroscopy based metabolomics analysis of serum. *Life Sci.*, **151**, 122–129.
- Spitali, P., Hettne, K., Tsonaka, R., Sabir, E., Seyer, A., Hemerik, J.B., Goeman, J.J., Picillo, E., Ergoli, M., Politano, L. and Aartsma-Rus, A. (2018) Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy. *J. Cell. Mol. Med.*, **22**, 2442–2448.
- Boca, S.M., Nishida, M., Harris, M., Rao, S., Cheema, A.K., Gill, K., Wang, D., An, L., Gauba, R., Seol, H. et al. (2016) Correction: Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. *PLoS One*, **11**, e0159895.
- Joseph, J., Cho, D. and Doles, J. (2018) Metabolomic analyses reveal extensive progenitor cell deficiencies in a mouse model of Duchenne muscular dystrophy. *Metabolites*, **8**, 61.
- Lee-McMullen, B., Chrzanowski, S.M., Vohra, R., Forbes, S.C., Vandenborne, K., Edison, A.S. and Walter, G.A. (2019) Age-dependent changes in metabolite profile and lipid saturation in dystrophic mice. *NMR Biomed.*, **32**, 1–11.
- Guiraud, S., Squire, S.E., Edwards, B., Chen, H., Burns, D.T., Shah, N., Babbs, A., Davies, S.G., Wynne, G.M., Russell, A.J. et al. (2015) Second-generation compound for the modulation of utrophin in the therapy of DMD. *Hum. Mol. Genet.*, **24**, 4212–4224.
- van Putten, M., Kumar, D., Hulsker, M., Hoogaars, W.M.H., Plomp, J.J., van Opstal, A., van Iterson, M., Admiraal, P., van Ommen, G.J.B., 't Hoen, P.A.C. and Aartsma-Rus, A. (2012) Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. *Neuromuscul. Disord.*, **22**, 406–417.

27. Bello, L. and Pegoraro, E. (2019) The “usual suspects”: genes for inflammation, fibrosis, regeneration, and muscle strength modify Duchenne muscular dystrophy. *J. Clin. Med.*, **8**, 649.
28. Pescatori, M., Broccolini, A., Minetti, C., Bertini, E., Bruno, C., D'amico, A., Bernardini, C., Mirabella, M., Silvestri, G., Giglio, V. et al. (2007) Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. *FASEB J.*, **21**, 1210–1226.
29. Chen, Y.W., Zhao, P., Borup, R. and Hoffman, E.P. et al. (2000) Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. *J. Cell Biol.*, **151**, 1321–1336.
30. Roberts, T.C., Blomberg, K.E.M., McClorey, G., Andaloussi, S.E.L., Godfrey, C., Betts, C., Coursindel, T., Gait, M.J., Edvard Smith, C. and Wood, M.J. (2012) Expression analysis in multiple muscle groups and serum reveals complexity in the MicroRNA Transcriptome of the mdx mouse with implications for therapy. *Mol. Ther. – Nucleic Acids*, **1**, e39.
31. Bakay, M., Zhao, P., Chen, J. and Hoffman, E.P. (2002) A web-accessible complete transcriptome of normal human and DMD muscle. *Neuromuscul. Disord.*, **12** Suppl 1, S125–S141.
32. Marotta, M., Ruiz-Roig, C., Sarria, Y., Peiro, J.L., Nuñez, F., Ceron, J., Munell, F. and Roig-Quilis, M. (2009) Muscle genome-wide expression profiling during disease evolution in mdx mice. *Physiol. Genomics*, **37**, 119–132.
33. Hathout, Y., Marathi, R.L., Rayavarapu, S. et al. (2014) Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. *Hum. Mol. Genet.*, **23**, 6458–6469.
34. Cynthia Martin, F., Hiller, M., Spitali, P., Oonk, S., Dalebout, H., Palmblad, M., Chaouch, A., Guglieri, M., Straub, V., Lochmüller, H. et al. (2014) Fibronectin is a serum biomarker for Duchenne muscular dystrophy. *Proteomics – Clin. Appl.*, **8**, 269–278.
35. Doran, P., Wilton, S.D., Fletcher, S. and Ohlendieck, K. (2009) Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. *Proteomics*, **9**, 671–685.
36. Mariot, V., Joubert, R., Hourdé, C., Féasson, L., Hanna, M., Muntoni, F., Maisonobe, T., Servais, L., Bogni, C., Le Panse, R. et al. (2017) Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. *Nat. Commun.*, **8**, 6–13.
37. Loubakos, A., Yau, N., De Bruijn, P., Hiller, M., Kozaczynska, K., Jean-Baptiste, R., Reza, M., Wolterbeek, R., Koeks, Z., Ayoglu, B. et al. (2017) Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. *Sci. Rep.*, **7**, 17888.
38. Srivastava, N.K., Yadav, R., Mukherjee, S. et al. (2018) Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: in vitro, high resolution NMR spectroscopy based analysis. *Clin. Chim. Acta*, **478**, 171–181.
39. Abdullah, M., Kornegay, J.N., Honcoop, A., Parry, T.L., Balog-Alvarez, C.J., O'Neal, S.K., Bain, J.R., Muehlbauer, M.J., Newgard, C.B., Patterson, C. and Willis, M.S. (2017) Non-targeted metabolomics analysis of golden retriever muscular dystrophy-affected muscles reveals alterations in arginine and proline metabolism, and elevations in glutamic and oleic acid in vivo. *Metabolites*, **7**, 1–19.
40. Newsholme, P., Lima, M.M.R., Procopio, J., Pithon-Curi, T.C., Doi, S.Q., Bazotte, R.B. and Curi, R. (2003) Glutamine and glutamate as vital metabolites. *Brazilian J. Med. Biol. Res. = Rev. Bras. Pesqui. medicas e Biol.*, **36**, 153–63.
41. Zielke, H.R., Zielke, C.L. and Ozand, P.T. (1984) Glutamine: a major energy source for cultured mammalian cells. *Fed. Proc.*, **43**, 121–125.
42. Griffin, J.L., Williams, H.J., Sang, E., Clarke, K., Rae, C. and Nicholson, J.K. (2001) Metabolic profiling of genetic disorders: a multitissue ¹H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue. *Anal. Biochem.*, **293**, 16–21.
43. Martins-Bach, A.B., Bloise, A.C., Vainzof, M., Rahnamaye Rabhani, S. (2012) Metabolic profile of dystrophic mdx mouse muscles analyzed with in vitro magnetic resonance spectroscopy (MRS). *Magn. Reson. Imaging*, **30**, 1167–1176.
44. Kinscherf, R., Hack, V., Fischbach, T., Friedmann, B., Weiss, C., Edler, L., Bärtsch, P. and Dröge, W. (1996) Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine. *J. Mol. Med.*, **74**, 393–400.
45. Kuhn, K.S., Muscaritoli, M., Wischmeyer, P. and Stehle, P. (2010) Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. *Eur. J. Nutr.*, **49**, 197–210.
46. Younkin, D.P., Berman, P., Sladky, J., Chee, C., Bank, W. and Chance, B. (1987) ³¹P NMR studies in Duchenne muscular dystrophy: age-related metabolic changes. *Neurology*, **37**, 165–9.
47. Newman, R.J., Bore, P.J., Chan, L., Gadian, D.G., Styles, P., Taylor, D. and Radda, G.K. (1982) Nuclear magnetic resonance studies of forearm muscle in Duchenne dystrophy. *Br. Med. J. (Clin. Res. Ed.)*, **284**, 1072–4.
48. Barbiroli, B., Funicello, R., Iotti, S., Montagna, P., Ferlini, A. and Zaniol, P. (1992) ³¹P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. *J. Neurol. Sci.*, **109**, 188–195.
49. Lindsay, A., Chamberlain, C.M., Witthuhn, B.A., Lowe, D.A., Ervasti, J.M. (2019) Dystrophinopathy-associated dysfunction of Krebs cycle metabolism. *Hum. Mol. Genet.*, **28**, 942–951.
50. Brinkmeyer-Langford, C., Chu, C., Balog-Alvarez, C., Yu, X., Cai, J.J., Nabity, M. and Kornegay, J.N. (2018) Expression profiling of disease progression in canine model of Duchenne muscular dystrophy. *PLoS One*, **13**, e0194485.
51. Cacchiarelli, D., Martone, J., Girardi, E., Cesana, M., Incitti, T., Morlando, M., Nicoletti, C., Santini, T., Sthandier, O., Barberi, L. et al. (2010) MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the Dystrophin/nNOS pathway. *Cell Metab.*, **12**, 341–351.
52. Lighthart-Melis, G.C. and Deutz, N.E.P. (2011) Is glutamine still an important precursor of citrulline? *Am. J. Physiol. Endocrinol. Metab.*, **301**, E264–E266.
53. Molza, A.-E., Mangat, K., Le Rumeur, E., Hubert, J.-F., Menhart, N. and Delalande, O. (2015) Structural basis of neuronal nitric-oxide synthase interaction with Dystrophin repeats 16 and 17. *J. Biol. Chem.*, **290**, 29531–29541.
54. Hafner, P., Bonati, U., Erne, B., Schmid, M., Rubino, D., Pohlman, U., Peters, T., Rutz, E., Frank, S., Neuhaus, C. et al. (2016) Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study. *PLoS One*, **11**, e0147634.
55. Hafner, P., Bonati, U., Rubino, D., Gocheva, V., Zumbunn, T., Gueven, N. and Fischer, D. (2016) Treatment with l-citrulline and metformin in Duchenne muscular dystrophy: study

- protocol for a single-centre, randomised, placebo-controlled trial. *Trials*, **17**, 389.
56. He, Y., Hakvoort, T.B.M., Köhler, S.E., Vermeulen, J.L.M., de Waart, D.R., de Theije, C., ten Have, G.A.M., van Eijk, H.M.H., Kunne, C., Labruyere, W.T., et al. (2010) Glutamine Synthetase in muscle is required for glutamine production during fasting and Extrahepatic ammonia detoxification. *J. Biol. Chem.*, **285**, 9516–9524.
 57. Thangarajh, M., Zhang, A., Gill, K., Ransom, H.W., Li, Z., Varghese, R.S., Hoffman, E.P., Nagaraju, K., Hathout, Y. and Boca, S.M. (2019) Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne. *PLoS One*, **14**, e0219507.
 58. Abu Bakar, M.H. and Sarmidi, M.R. (2017) Association of cultured myotubes and fasting plasma metabolite profiles with mitochondrial dysfunction in type 2 diabetes subjects. *Mol. Biosyst.*, **13**, 1838–1853.
 59. Rodríguez-Cruz, M., Cruz-Guzmán, O.R., Escobar, R.E., López-Alarcón, M. (2016) Leptin and metabolic syndrome in patients with Duchenne/Becker muscular dystrophy. *Acta Neurol. Scand.*, **133**, 253–260.
 60. Mynatt, R.L., Noland, R.C., Elks, C.M., Vandanmagsar, B., Bayless, D.S., Stone, A.C., Ghosh, S., Ravussin, E., Warfel, J.D. (2019) The RNA binding protein HuR influences skeletal muscle metabolic flexibility in rodents and humans. *Metabolism*, **97**, 40–49.
 61. Fitzmaurice, G.M., Laird, N.M. and Ware, J.H. (2011) *Applied longitudinal analysis*. Wiley, Hoboken, New Jersey, 2011.
 62. van, M., de Winter, C., van Roon-Mom, W., van Ommen, G.-J., 't Hoen, P.A.C. and Aartsma-Rus, A. (2010) A 3 months mild functional test regime does not affect disease parameters in young mdx mice. *Neuromuscul. Disord.*, **20**, 273–80.
 63. Dunn, W.B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., Brown, M., Knowles, J.D., Halsall, A., Haselden, J.N. et al. (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nat. Protoc.*, **6**, 1060–1083.
 64. Sumner, L.W., Amberg, A., Barrett, D., Beale, M.H., Beger, R., Daykin, C.A., Fan, T.W.M., Fiehn, O., Goodacre, R., Griffin, J.L. et al. (2007) Proposed minimum reporting standards for chemical analysis. *Metabolomics*, **3**, 211–221.
 65. van den Berg, R.A., Hoefsloot, H.C.J., Westerhuis, J.A., Smilde, A.K. and van der Werf, M.J. (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. *BMC Genomics*, **7**, 142.
 66. McCulloch, C.E., Searle, S.R. and Neuhaus, J.M. (2008) *Generalized, Linear, and Mixed Models*, 2nd Edition; Wiley, Hoboken, New Jersey, (2008).
 67. Benjamini, Y. and Hochberg, Y. (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Source J. R. Stat. Soc. Ser. B*, **57**, 289–300.
 68. Goeman, J.J., Van de, S., De Kort, F. and van Houwelingen, H.C. (2004) A global test for groups of genes: testing association with a clinical outcome. *Bioinformatics*, **20**, 93–99.
 69. Slenter, D.N., Kutmon, M., Hanspers, K., Riutta, A., Windsor, J., Nunes, N., Mélius, J., Cirillo, E., Coort, S.L., Digles, D. et al. (2018) WikiPathways: A multifaceted pathway database bridging metabolomics to other omics research. *Nucleic Acids Res.*, **46**, D661–D667.
 70. Kelder, T., Pico, A.R., Hanspers, K., van Iersel, M.P., Evelo, C. and Conklin, B.R. (2009) Mining biological pathways using WikiPathways web services. *PLoS One*, **4**, e6447.
 71. Wolstencroft, K., Haines, R., Fellows, D., Williams, A., Withers, D., Owen, S., Soiland-Reyes, S., Dunlop, I., Nenadic, A., Fisher, P. et al. (2013) The Taverna workflow suite: designing and executing workflows of web services on the desktop, web or in the cloud. *Nucleic Acids Res.*, **41**, W557–W561.
 72. Westfall, P.H. and Troendle, J.F. (2008) Multiple testing with minimal assumptions. *Biometrical J.*, **50**, 745–755.
 73. <https://software.broadinstitute.org/morpheus>.
 74. Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D. and R Core Team (2018) *Linear and Nonlinear Mixed Effects Models. R package nlme version 3.1-137*. Comprehensive R Archive Network (CRAN), (2018).
 75. Karnovsky, A., Weymouth, T., Hull, T., Tarcea, V.G., Scardoni, G., Laudanna, C., Sartor, M.A., Stringer, K.A., Jagadish, H.V., Burant, C. et al. (2012) Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. *Bioinformatics*, **28**, 373.
 76. Shannon, P. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.*, **13**, 2498–2504.